As a result of this mode of action, TZDs promote healthy fat mass gain, improving dyslipidaemia, insulin sensitivity and glycaemic control (Kelly et al. 1999, Mori et al. 1999, Miyazaki et al. 2001, Shadid & Jensen 2003), confirming the role of AT expandability in metabolic impairment pathogenesis. This evidence concerns the gene INS and inherited lipid metabolism disorder.